Healthcare Industry News:  RGN-137 

Biopharmaceuticals

 News Release - January 21, 2010

RegeneRx Biopharmaceuticals, Inc. Moving to New Corporate Office Space

BETHESDA, Md.--(HSMN NewsFeed)--REGENERX BIOPHARMACEUTICALS, INC. (NYSE Amex:RGN) announced today that it is moving its corporate headquarters from Bethesda, Maryland to the Maryland I-270 Technology Corridor in Rockville, Maryland, effective January 22, 2010. The companys offices will be closed on that day to complete the move.

The new headquarters, located at 15245 Shady Grove Road, Suite 470, Rockville, Maryland, 20850, phone number (301-208-9191), will house seven of the companys nine full-time employees and provides for future expansion.

C. Neil Lyons, chief financial officer stated, While we continue to operate a lean, outsourced business model, our new location provides us with larger office space that is better suited to our operations, at reduced cost. Additionally, positioning ourselves in closer proximity to some of our vendors, peer bioscience companies, and industry colleagues greatly facilitates our ability to transact business.

About RegeneRx Biopharmaceuticals, Inc.

RegeneRx is focused on the discovery and development of novel peptides to accelerate tissue and organ repair. Currently, RegeneRx is developing four product candidates, RGN-137, RGN-259, RGN-352 and RGN-457 for dermal, ophthalmic, and cardiovascular tissue repair; and pulmonary disorders, respectively. These product candidates are based on T4, a synthetic copy of a 43-amino acid, naturally occurring peptide, in part, under an exclusive world-wide license from the National Institutes of Health. RegeneRx holds over 60 world-wide patents and patent applications related to novel peptides. It is currently sponsoring a Phase II clinical trial for dermal wound healing and has recently completed a Phase I clinical trial supporting delivery of RGN-352 for acute cardiovascular and other indications requiring its systemic administration. RegeneRx is also developing novel peptides for the cosmeceutical industry based on its experience with T4 and its biological activities in the skin.

RegeneRx Technology Background

T4 is a synthetic version of a naturally occurring peptide present in virtually all human cells. It is a first-in-class, multi-faceted molecule that promotes endothelial cell differentiation, angiogenesis in dermal tissues, keratinocyte migration, and collagen deposition, while down-regulating inflammation. RegeneRx has identified several molecular variations of T4 that may affect the aging of skin, among other properties, and could be important candidates as active ingredients in pharmaceutical and consumer products. Researchers at the National Institutes of Health, and at other academic institutions throughout the world, have published numerous scientific articles indicating T4s in vitro and in vivo efficacy in accelerating wound healing and tissue protection under a variety of conditions. Abstracts of scientific papers related to T4s mechanisms of action may be viewed at RegeneRxs web page: www.regenerx.com.


Source: RegeneRx Biopharmaceuticals

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.